Women With Recurrent Ovarian Cancer With Maintenance Use Of Rucaparib May Have Longer Quality-Adjusted PFS And Quality-Adjusted Time Without Symptoms Or Toxicity Compared To Placebo

Cancer Therapy Advisor (9/3, Moench) reports researchers conducted an exploratory analysis and found “longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity in women with recurrent ovarian cancer treated with maintenance use of” rucaparib, a PARP inhibitor, “compared with placebo.” The findings were published in the Journal of Clinical Oncology.